Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4046)
All Articles published online
|
Publishing Process of This Article
|
Nov 15, 2023 (publication date) through Dec 10, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Feng R, Cheng DX, Chen XC, Yang L, Wu H. Application of sintilimab combined with anlotinib hydrochloride in the clinical treatment of microsatellite stable colorectal cancer. World J Gastrointest Oncol 2023; 15(11): 1925-1935 [PMID: 38077647 DOI: 10.4251/wjgo.v15.i11.1925] |
|
|
|
| ©2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Feng R, Cheng DX, Chen XC, Yang L, Wu H. Application of sintilimab combined with anlotinib hydrochloride in the clinical treatment of microsatellite stable colorectal cancer. World J Gastrointest Oncol 2023; 15(11): 1925-1935 [PMID: 38077647 DOI: 10.4251/wjgo.v15.i11.1925] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i11/1925.htm |
| Number | Citing Articles |
| 1 |
Mateusz Kciuk, Katarzyna Wanke, Weronika Kruczkowska, Beata Marciniak, Renata Kontek. Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review. Molecules 2025; 30(13): 2686 doi: 10.3390/molecules30132686
|
| 2 |
Hongfei Liu, Xuezhi Chang, Ye Hong, Hao Yin, Haiyan Zhang, Gulizhaer Wufuer, Shabiremu Abuduaini, Yali Jiang. Efficacy and safety of anlotinib hydrochloride combined with concurrent radiotherapy in the treatment of locally advanced cervical cancer: a single-arm, single-center, exploratory, phase II clinical study. Frontiers in Oncology 2025; 15 doi: 10.3389/fonc.2025.1662160
|